Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zamzetoclax
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zamzetoclax, also known by its former code name GS-9716, is an orally bioavailable small molecule developed by Gilead Sciences. It was investigated for the treatment of advanced solid malignancies. The drug functions as a selective inhibitor of the anti-apoptotic protein myeloid cell leukemia 1 (MCL1), aiming to promote programmed cell death (apoptosis) in cancer cells that overexpress MCL1.
02
Targets
MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on zamzetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zamzetoclax.